Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ImmunoGen Inc
IMGN
Healthcare
Biotechnology
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once...
the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:IMGN)
New Post
View:
Posts & Comments
Threaded Posts
(15)
•••
HDavis
X
Post by
HDavis
on Dec 01, 2021 10:02pm
IMGN - Wednesday Rundown, Thursday Expectations
(15)
•••
HDavis
X
Post by
HDavis
on Nov 30, 2021 11:26pm
IMGN - Tuesday Rundown, Wednesday Expectations
(15)
•••
HDavis
X
Post by
HDavis
on Nov 30, 2021 3:58pm
IMGN - Is Set Up For A Run
(668)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Feb 25, 2020 8:46pm
this one is holding up well
considering the markets,so glta shareholders.
(668)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Feb 14, 2020 1:24pm
still holding this stock
my new target price for this year is over $10 plus per share and MORE,so glta shareholders.
(668)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Feb 14, 2020 1:15pm
past my target price
but won't sell it yet,my target was the $6 per share mark,but because this stock blew past it with all kinds of strength showing on my chart,my greed is taking over for me,please,Sir,but I want
...more
(668)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Dec 17, 2019 10:39am
still holding this stock
got it about 7 months ago for $1.87 per share,my target is at $6 per share,which would be a triple for me,so glta.
(668)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on May 06, 2019 11:07am
it's a buy today for me
another breakout story today in these bad markets,so glta opportunists out there.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Gander Gold Discovers Significant Gold System at Lizard Pond Claims – Gander South Project
AI Alchemy: Turning Data into Gold with Artificial Intelligence